

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3335749

<b>SUBMISSION TYPE:</b>	CORRECTIVE ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Corrective Assignment to correct the ASSIGNEE previously recorded on Reel 035499 Frame 0586. Assignor(s) hereby confirms the ASSIGNEE.
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SYPHASE, LLC	12/31/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CONCENTRX PHARMACEUTICALS, INC.
<b>Street Address:</b>	PO BOX 16711
<b>City:</b>	CHAPEL HILL
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27516
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14343498
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(919)848-5032
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	9192568196
<b>Email:</b>	leah@passeip.com
<b>Correspondent Name:</b>	PASSE INTELLECTUAL PROPERTY, LLC
<b>Address Line 1:</b>	1717 BRASSFIELD RD
<b>Address Line 4:</b>	RALEIGH, NORTH DAKOTA 27614
<b>NAME OF SUBMITTER:</b>	JAMES G. PASSE
<b>SIGNATURE:</b>	/James G. Passe/
<b>DATE SIGNED:</b>	05/01/2015
<b>Total Attachments: 4</b>	
source=SYPH001AssignmentToConcentrx2015#page1.tif	
source=SYPH001AssignmentToConcentrx2015#page2.tif	
source=SYPH001AssignmentToConcentrx2015#page3.tif	
source=SYPH001IncorrectCoverSheetConcentrx#page1.tif	

## ASSIGNMENT OF PATENTS

This ASSIGNMENT OF PATENTS, dated December 31, 2014, is entered into by SYPHASE, LLC, an Arizona limited liability company, and Eric C. Richardson (collectively, "Assignor"), for the benefit of Concentrx Pharmaceuticals, Inc., a Delaware corporation ("Assignee").

WHEREAS, Assignee and Assignor have entered into that certain Contribution Agreement, dated as of the date hereof (the "Agreement"), pursuant to which Assignor has agreed to sell and assign, and Assignee has agreed to buy and acquire certain intellectual property to Assignee; and

WHEREAS, pursuant to the Agreement, Assignor desires to assign, to the extent not previously assigned to the Assignee, to Assignee all of Assignor's right, title and interest in and to the patents, patent applications, patent disclosure and related patent rights (the "Patents") set forth on Schedule 1 attached hereto.

NOW, THEREFORE, in consideration of entering into the Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns, set overs and transfers to Assignee, its successors and assigns all of Assignor's entire rights, title and interests in and to the Patents, and agrees to sell, assign, set over and transfer to Assignee, its successors and assigns all of Assignor's entire right, title and interest in and to the Patents that are completed or come into existence hereafter, including any divisions, continuations, re-examinations, or reissues, and extensions thereof, and all rights of priority resulting from the filing in the United States of the Patents, and any and all applications for patent and patents issuing therefrom in any and all countries of the world, including all divisions, continuations, re-examinations, or reissues, and extensions thereof, and all rights of priority resulting from the filing in the United States of the respective applications for said Patents identified above, the same to be held and enjoyed by Assignee for its own use and enjoyment, and for the use and enjoyment of its successors, assigns and other legal representatives, to the end of the term or terms for which the Patents are or may be granted or reissued as fully and entirely as the same would have been held and enjoyed by the Assignor if this Assignment and sale had not been made; together with all claims for damages by reason of past infringements of the Patents including without limitation provisional rights thereto with the right to sue for and collect the same for its own use and benefit, and for the use and on behalf of its successors, assigns and other legal representatives; provided, however, Assignee will be responsible for those costs and expenses reasonably incurred by Assignor in carrying out Assignor's obligations pursuant to this paragraph.

Assignor agrees that, on request it will at Assignee's expense sign all lawful papers in connection with all divisional, continuing, re-examining and reissue applications, make all rightful oaths and generally do everything reasonably requested by Assignee to aid Assignee, its successors, assigns and nominees to obtain, maintain, and enforce patent protection in any country for the inventions set forth in the Patents.

[Signature page to follow.]

IN WITNESS WHEREOF, Assignor has executed this Assignment effective this 31st day  
of December 2014.

SYPHASE, LLC

By: E. C. Richardson

Name: ERIC C. RICHARDSON

Title: OWNER

ERIC C. RICHARDSON

By: E. C. Richardson

Schedule 1

Disposable Unit Dose Dry Powder Inhaler Technology;

1. US provisional patent application no. 61,573,496, filed Sept. 7, 2011, entitled "Dry Powder Inhalation Device";
2. US patent application no. 20140230817 entitled "Dry Powder Inhalation Device";
3. Canadian patent application no. CA2846899A1 entitled "Dry Powder Inhalation Device";
4. European Patent Office patent application no. EP2747815A2 entitled "Dry Powder Inhalation Device";
5. Patent Cooperation Treaty patent application no. PCT/US2012/054325 entitled "Dry Powder Inhalation Device"; and
6. all patents, patent applications, and other patent rights claiming priority to any of the foregoing or claiming subject matter described in any of the foregoing, which shall include, but not be limited to, (a) any continuations, continuations-in-part, divisionals, provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations, re-examinations, renewals, or reissues of any of the foregoing, (b) any patents issuing on any of the foregoing, and (c) any foreign counterpart of any of the foregoing.

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3327240

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SYPHASE, LLC	12/31/2014
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CONCENTRX PHARMACEUTICALS, LLC
<b>Street Address:</b>	PO BOX 16711
<b>City:</b>	CHAPEL HILL
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27516
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14343498
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(919)848-5032
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	919-256-8199
<b>Email:</b>	leah@passeip.com
<b>Correspondent Name:</b>	PASSE INTELLECTUAL PROPERTY, LLC
<b>Address Line 1:</b>	1717 BRASSFIELD RD
<b>Address Line 4:</b>	RALEIGH, NORTH CAROLINA 27614
<b>NAME OF SUBMITTER:</b>	JAMES G. PASSE
<b>SIGNATURE:</b>	/James G. Passe/
<b>DATE SIGNED:</b>	04/27/2015
<b>Total Attachments: 3</b>	
source=SYPH001AssignmentToConcentrx2015#page1.tif	
source=SYPH001AssignmentToConcentrx2015#page2.tif	
source=SYPH001AssignmentToConcentrx2015#page3.tif	